66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02160132 (ClinicalTrials.gov) | June 2014 | 3/6/2014 | A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes. | Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. | Glomerulonephritis, IGA;Peripapillary Crescent;Necrosis;Steroid Nephropathy | Drug: Methylprednisolone(intravenously in the 1st-2nd-3rd month );Drug: Methylprednisolone(intravenously in the 1st-3rd-5th month) | Sun Yat-sen University | NULL | Recruiting | 14 Years | 65 Years | Both | 180 | Phase 2 | China |